However, AhR antagonists also lower IL-22; therefore, studies of partial agonists/antagonists at this receptor are needed as these agents have the ability to selectively target AhR, avoiding adverse effects such as metabolic syndrome or IL-22 downregulation [317,318]. This evidence concerns the gene IL22 and metabolic syndrome.